Chronic lymphocytic leukemia – Wikipedia
Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.
Mantle Cell Lymphoma: Practice Essentials, Overview
Feb 11, 2018 · Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles.
Cancer immunotherapy – Wikipedia
Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system’s natural ability to fight cancer.It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.It exploits the fact that cancer cells often have molecules on their surface that can be detected by the
What’s New in Non-Hodgkin Lymphoma Research and Treatment?
Aug 01, 2018 · Research into the causes, prevention, and treatment of non-Hodgkin lymphoma (NHL) is being done in many medical centers throughout the world. Scientists are making a lot of progress in understanding how changes in the DNA inside normal lymphocytes can cause them to develop into lymphoma cells. Once
Hematopoietic Colony-Stimulating Factors (CSFs) – Medical
For the short acting granulocyte colony-stimulating factors (G-CSFs), Filgrastim-sndz (Zarxio) and filgrastim-aafi (Nivestym) are considered the least costly short acting G-CSFs to Aetna. There are several brands and biosimilars of short acting G-CSFs on the market, including filgrastim (Neupogen
Media – AstraZeneca US
Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data.
Interferons – Medical Clinical Policy Bulletins | Aetna
Number: 0404. Policy. Subject to the qualification described below regarding length of treatment and response to treatment, Aetna considers interferon alfa, pegylated interferon, interferon beta, and interferon gamma medically necessary for persons who meet the criteria for each drug specified below.
Martin S. Tallman | Memorial Sloan Kettering Cancer Center
I am a board-certified hematologist and oncologist and Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center.
About Immuno-Oncology – Immuno-Oncology News
Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment.
Rare Disease List – Global Genes
The RARE List™ is comprised of approximately 7,000 different rare diseases and disorders affecting more than 300 million people worldwide. More RARE Facts™ can be found here. We are often asked why some common diseases are included on the RARE List™. The answer is two fold:This is a list of rare diseases defined in the United States where a prevalence of less than 200,000 cases is the